CSL

• Country: LU

Sofrimento no trabalho. CSL oferece consultas gratuitas de apoio psicológico aos trabalhadores no Luxemburgo

Sentimentos de injustiça, conflitos com a hierarquia, colegas ou excesso de trabalho. São várias as causas de stress no trabalho que perturbam a saúde dos trabalhadores. A Câmara dos Assalariados do Luxemburgo oferece apoio psicológico gratuito.

• Press releases
• Country: United States

CSL und Alentis geben weltweite Partnerschaft zur Entwicklung und Vermarktung von lixudebart für seltene Nieren- und Lebererkrankungen bekannt

Alentis erhält erste Zahlung in Höhe von 355 Millionen US-Dollar sowie bis zu 1,2 Milliarden US-Dollar an kommerziellen Meilensteinzahlungen, die weltweiten Gewinne werden geteilt MELBOURNE, Australien, und BASEL, Schweiz, 6. Oktober 2026 /PRNewswire/ -- CSL und Alentis Therapeutics gaben...

• Press releases
• Country: United States

CSL et Alentis annoncent un partenariat mondial visant à développer et à mettre sur le marché le lixudebart pour le traitement de maladies rares des reins et du foie

Alentis percevra un versement initial de 355 millions USD et jusqu'à 1,2 milliard USD de jalons commerciaux, avec un partage des profits à l'échelle mondiale MELBOURNE, Australie et BÂLE, Suisse, 5 octobre 2026 /PRNewswire/ -- CSL et Alentis Therapeutics annoncent aujourd'hui avoir conclu...

• Press releases
• Country: United States

CSL y Alentis desarrollarán y comercializarán lixudebart para enfermedades renales y hepáticas raras

- CSL y Alentis anuncian una colaboración global para desarrollar y comercializar lixudebart para enfermedades renales y hepáticas raras Alentis recibirá un pago inicial de 355 millones de dólares y hasta 1.200 millones de dólares por hitos comerciales, con reparto de beneficios a nivel...

• Country: United States

CSL strikes $1.55B lixudebart deal with Alentis for rare kidney and liver diseases

• Country: Cyprus

CSL to pay up to $1.6 bln to develop rare disease drug; shares rise

• Country: Australia

CSL to pay $2.3b in lixudebart rare disease drug deal with Alentis Therapeutics

CSL has agreed to pay as much as $2.3 billion to jointly develop and sell an experimental treatment for rare kidney and liver diseases, expanding the biotech company’s push into kidney medicine.

• Country: United States

CSL strikes $1.6B deal with Alentis for experimental kidney, liver drug

• Press releases
• Country: United States

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global...

• Country: Malaysia

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an... The post CSL and…